Evidence map›Paper›PMID 40092701›Full record

ArticleJournal of Cancer2025

CCL4 and MIF: Prognostic Biomarkers for Evaluating the Chemoradiotherapy Response and Prognosis in Patients with ESCC.

Yuwen Wang, Chunxue Ding, Xiaoying Wei, Yuting Li, Xuyao Yu, Xi Chen, Jifeng Sun, Junhong Zhuang, Shuai Cao, Peng Zhen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuwen WangDepartment of Radiation Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Chunxue DingDepartment of Radiation Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Xiaoying WeiDepartment of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Yuting LiDepartment of Radiation Oncology, Department of Pathology, Life Science Research Center, The First Affiliated Hospital of Xinxiang Medical University, China.
Xuyao YuDepartment of Radiation Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Xi ChenDepartment of Radiation Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Jifeng SunDepartment of Radiation Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Junhong ZhuangDepartment of Radiation Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Shuai CaoDepartment of Radiation Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Peng ZhenDepartment of Radiation Oncology, Chifeng Tumor Hospital, Chifeng, China.
Fang FangDepartment of Radiation Oncology, Chifeng Tumor Hospital, Chifeng, China.
Jiarui ZhangDepartment of Radiation Oncology, Chifeng Tumor Hospital, Chifeng, China.
Jun WangDepartment of Radiation Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Dong QianDepartment of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Qingsong PangDepartment of Radiation Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CCL4chemoradiotherapyESCCimmune infiltrationMIF

Identifiers

PMID40092701
PMCPMC11905412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.